Industrial and Organizational Mutations in the Medical and Pharmaceutical Sectors Impulsed by Open Innovation During the Pandemic

Laurent Adatto, Camille Aouinaït, Son Thi Kim Le () and Michelle Mongo ()
Additional contact information
Laurent Adatto: ISI - Centre de recherche sur l’Innovation et les Stratégies Industrielles - ULCO - Université du Littoral Côte d'Opale, RRI - Réseau de Recherche sur l'Innovation
Camille Aouinaït: RRI - Réseau de Recherche sur l'Innovation
Son Thi Kim Le: ISI - Centre de recherche sur l’Innovation et les Stratégies Industrielles - ULCO - Université du Littoral Côte d'Opale, ISCID-CO - Institut Supérieur de Commerce International de Dunkerque Côte d'Opale - ULCO - Université du Littoral Côte d'Opale, RRI - Réseau de Recherche sur l'Innovation
Michelle Mongo: Mines Saint-Étienne MSE - École des Mines de Saint-Étienne - IMT - Institut Mines-Télécom [Paris], COACTIS - COnception de l'ACTIon en Situation - UL2 - Université Lumière - Lyon 2 - UJM - Université Jean Monnet - Saint-Étienne, FAYOL-ENSMSE - Institut Henri Fayol - Mines Saint-Étienne MSE - École des Mines de Saint-Étienne - IMT - Institut Mines-Télécom [Paris], FAYOL-ENSMSE - Département Management responsable et innovation - ENSM ST-ETIENNE - Ecole Nationale Supérieure des Mines de St Etienne - Institut Henri Fayol

Post-Print from HAL

Abstract: The Covid-19 pandemic tragically emphasized severe failures of health systems. In particular, the saturation of hospital infrastructures and the lack of medical devices, as the crucial respiratory ventilators. The medical and pharmaceutical sectors had to find urgently new ways to innovate efficiently in R&D, to product devices, therapeutic trials and vaccines, and make them available on a large scale. Our work will analyze that these innovations related to Covid-19 have been largely based on Open Innovation. For that purpose, exploratory cases studies that exemplified the value of implementing Open Innovation in the pandemic context will be shown. These cases studies concern the pharmaceutical firms AstraZeneca, and Pfizer associated with the biotechnology company BioNTech, and the respiratory ventilator cases of open development coalition OxyGEN (from the design company Protofy.xyz to the hospitals network of Barcelona and the manufacturer SEAT) and the opening of Covidian PB 560 from the multinational medical engineering firm Medtronic. Methodologically, these cases studies build on a full referencing and a systematic analysis of articles, scientific documents, published reports related to the Open Innovation involvements of these organizations since the start of the pandemic. Based on the operative contributions from these revelatory cases studies, we will be able to show that contextually to pandemic emergency, Open Innovation is a highly efficient vector allowing extended partnerships for accelerated R&D, and operational production.

Keywords: Open Innovation; Covid-19 Pandemic; Pharmaceutical Industry; Medical Devices; Cases Studies (search for similar items in EconPapers)
Date: 2022-06-17
References: Add references at CitEc
Citations:

Published in The 8th ENTerprise REsearch InNOVAtion Conference – ENTRENOVA, IRENET - Society for Advancing Innovation and Research in Economy, Jun 2022, Opatija, Croatia. pp.421-434, ⟨10.54820/entrenova-2022-0035⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:emse-03699297

DOI: 10.54820/entrenova-2022-0035

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().